Abstract

Background: Previously published studies have indicated that lymphoid enhancer-binding factor 1 (LEF1) expression could be recognized as a valuable biomarker to evaluate clinical outcome for various types of malignant cancer, but the results remained controversial. Therefore, we conducted this meta-analysis to pool the published estimates and discuss the relationship of LEF1 expression with cancer prognosis. Methods: Five electronic databases Pubmed, Web of Science, Embase, CNKI, and Wanfang were systematically searched for eligible literatures. Hazard ratios (HRs) and 95% confidence intervals (CIs) from the included studies were combined to estimate the effect of LEF1 expression on cancer patients’ survival. Results: Eleven original studies met the criteria and were enrolled for analysis. The results indicated that compared with patients in low LEF1 expression group, patients in high LEF1 expression group tended to have shorter overall survival (HR = 1.74, 95% CI: 1.06–2.86, P=0.029), especially for patients with solid tumors (HR = 2.39, 95% CI: 1.86–3.08, P=0.000). Conclusions: Individual evidence about the prognostic value of LEF1 expression in human cancers was limited. Our meta-analysis supported the suggestion that elevated LEF1 expression could function as a promising biomarker to predict the clinical outcomes for malignant cancers, especially solid tumors. More high-quality clinical studies are warranted to highlight the prognostic value of LEF1 expression in human cancers.

Highlights

  • As a major cause of mortality worldwide, malignant cancer has become a huge health problem for human beings [1]

  • Through carefully screening the titles and abstracts, 134 articles were discarded for not reporting the association of lymphoid enhancer-binding factor 1 (LEF1) expression with cancer prognosis

  • In colorectal cancer (CRC), LEF1 overexpression was positively detected in 44% of cancer patients by tissue microarray (TMA) analysis and significantly correlated with shorter overall survival (OS) and subsequent occurrence of liver metastasis [22]

Read more

Summary

Introduction

As a major cause of mortality worldwide, malignant cancer has become a huge health problem for human beings [1]. Published studies have indicated that lymphoid enhancer-binding factor 1 (LEF1) expression could be recognized as a valuable biomarker to evaluate clinical outcome for various types of malignant cancer, but the results remained controversial. We conducted this meta-analysis to pool the published estimates and discuss the relationship of LEF1 expression with cancer prognosis. Our meta-analysis supported the suggestion that elevated LEF1 expression could function as a promising biomarker to predict the clinical outcomes for malignant cancers, especially solid tumors. More high-quality clinical studies are warranted to highlight the prognostic value of LEF1 expression in human cancers

Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.